{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,17]],"date-time":"2026-08-17T17:46:27Z","timestamp":1786988787770,"version":"build-2736575974"},"reference-count":29,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2018,12,1]],"date-time":"2018-12-01T00:00:00Z","timestamp":1543622400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2018,12,1]],"date-time":"2018-12-01T00:00:00Z","timestamp":1543622400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2019,10,5]],"date-time":"2019-10-05T00:00:00Z","timestamp":1570233600000},"content-version":"am","delay-in-days":308,"URL":"http:\/\/www.elsevier.com\/open-access\/userlicense\/1.0\/"}],"funder":[{"name":"Epilepsy Therapy Project"},{"DOI":"10.13039\/100001244","name":"Milken Family Foundation","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100001244","id-type":"DOI","asserted-by":"publisher"}]},{"name":"Elsie and Isaac Fogelman Endowment, Eisai"},{"DOI":"10.13039\/501100013327","name":"Lundbeck","doi-asserted-by":"crossref","id":[{"id":"10.13039\/501100013327","id-type":"DOI","asserted-by":"crossref"}]},{"name":"INSYS"},{"DOI":"10.13039\/100014114","name":"GW Pharmaceuticals","doi-asserted-by":"crossref","id":[{"id":"10.13039\/100014114","id-type":"DOI","asserted-by":"crossref"}]},{"name":"UCB"},{"name":"NIH","award":["R34MH089299"],"award-info":[{"award-number":["R34MH089299"]}]},{"DOI":"10.13039\/100004337","name":"Roche","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004337","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100004336","name":"Novartis","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004336","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100004319","name":"Pfizer","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004319","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100014597","name":"LAM Therapeutics","doi-asserted-by":"crossref","id":[{"id":"10.13039\/100014597","id-type":"DOI","asserted-by":"crossref"}]},{"name":"Novartis Pharmaceuticals"},{"name":"Novartis Pharmaceuticals Inc."},{"name":"Today and Tomorrow Children\u2019s Fund, Department of Defense\/ Congressionally Directed Medical Research Program"},{"name":"National Institute of Neurological Diseases and Stroke","award":["U01-NS082320"],"award-info":[{"award-number":["U01-NS082320"]}]},{"name":"National Institute of Neurological Diseases and Stroke","award":["P20-NS080199"],"award-info":[{"award-number":["P20-NS080199"]}]},{"name":"National Institute of Neurological Diseases and Stroke","award":["R01-NS082649"],"award-info":[{"award-number":["R01-NS082649"]}]},{"name":"Elsie and Isaac Fogelman Endowment"},{"name":"Hughes Family Foundation"},{"name":"UCLA Children\u2019s Discovery and Innovation Institute"},{"DOI":"10.13039\/100000005","name":"Department of Defense","doi-asserted-by":"crossref","award":["W81XWH-11-1-0365"],"award-info":[{"award-number":["W81XWH-11-1-0365"]}],"id":[{"id":"10.13039\/100000005","id-type":"DOI","asserted-by":"crossref"}]},{"DOI":"10.13039\/100000090","name":"Congressionally Directed Medical Research Program","doi-asserted-by":"crossref","id":[{"id":"10.13039\/100000090","id-type":"DOI","asserted-by":"crossref"}]},{"name":"Today\u2019s and Tomorrow\u2019s Children Fund from UCLA Mattel Children\u2019s Hospital"},{"name":"Developmental Synaptopathies Consortium","award":["U54NS092090"],"award-info":[{"award-number":["U54NS092090"]}]},{"DOI":"10.13039\/100006108","name":"NCATS","doi-asserted-by":"crossref","id":[{"id":"10.13039\/100006108","id-type":"DOI","asserted-by":"crossref"}]},{"DOI":"10.13039\/100000025","name":"National Institute of Mental Health","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100000025","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000071","name":"National Institute of Child Health and Human Development","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100000071","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100006108","name":"National Center for Advancing Translational Sciences","doi-asserted-by":"publisher","award":["8UL1TR000077"],"award-info":[{"award-number":["8UL1TR000077"]}],"id":[{"id":"10.13039\/100006108","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100006108","name":"National Center for Advancing Translational Sciences","doi-asserted-by":"publisher","award":["UL1RR033176"],"award-info":[{"award-number":["UL1RR033176"]}],"id":[{"id":"10.13039\/100006108","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Epilepsy Research"],"published-print":{"date-parts":[[2018,12]]},"DOI":"10.1016\/j.eplepsyres.2018.09.016","type":"journal-article","created":{"date-parts":[[2018,10,1]],"date-time":"2018-10-01T22:01:41Z","timestamp":1538431301000},"page":"1-7","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":33,"special_numbering":"C","title":["High vigabatrin dosage is associated with lower risk of infantile spasms relapse among children with tuberous sclerosis complex"],"prefix":"10.1016","volume":"148","author":[{"given":"Shaun A.","family":"Hussain","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ernst","family":"Schmid","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jurriaan M.","family":"Peters","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Monisha","family":"Goyal","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"E. Martina","family":"Bebin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hope","family":"Northrup","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mustafa","family":"Sahin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Darcy A.","family":"Krueger","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Joyce Y.","family":"Wu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Deborah","family":"Pearson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marian E.","family":"Williams","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ellen","family":"Hanson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nicole","family":"Bing","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bridget","family":"Kent","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sarah","family":"O\u2019Kelley","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rajna","family":"Filip-Dhima","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kira","family":"Dies","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stephanie","family":"Bruns","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Benoit","family":"Scherrer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gary","family":"Cutter","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Donna S.","family":"Murray","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Steven L.","family":"Roberds","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.eplepsyres.2018.09.016_bib0005","doi-asserted-by":"crossref","first-page":"1627","DOI":"10.1111\/j.1528-1157.1999.tb02049.x","article-title":"Randomised, placebo-controlled study of vigabatrin as first-line treatment of infantile spasms","volume":"40","author":"Appleton","year":"1999","journal-title":"Epilepsia"},{"key":"10.1016\/j.eplepsyres.2018.09.016_bib0010","doi-asserted-by":"crossref","first-page":"375","DOI":"10.1542\/peds.97.3.375","article-title":"High-dose corticotropin (ACTH) versus prednisone for infantile spasms: a prospective, randomized, blinded study","volume":"97","author":"Baram","year":"1996","journal-title":"Pediatrics"},{"key":"10.1016\/j.eplepsyres.2018.09.016_bib0015","doi-asserted-by":"crossref","first-page":"389","DOI":"10.1016\/S0920-1211(96)01006-6","article-title":"Randomized trial comparing vigabatrin and hydrocortisone in infantile spasms due to tuberous sclerosis","volume":"26","author":"Chiron","year":"1997","journal-title":"Epilepsy Res."},{"key":"10.1016\/j.eplepsyres.2018.09.016_bib0020","doi-asserted-by":"crossref","first-page":"1297","DOI":"10.1111\/j.1528-1167.2010.02564.x","article-title":"Vigabatrin-associated reversible MRI signal changes in patients with infantile spasms","volume":"51","author":"Dracopoulos","year":"2010","journal-title":"Epilepsia"},{"key":"10.1016\/j.eplepsyres.2018.09.016_bib0025","doi-asserted-by":"crossref","first-page":"180","DOI":"10.1136\/bmj.314.7075.180","article-title":"Severe persistent visual field constriction associated with vigabatrin","volume":"314","author":"Eke","year":"1997","journal-title":"BMJ"},{"key":"10.1016\/j.eplepsyres.2018.09.016_bib0030","doi-asserted-by":"crossref","first-page":"1416","DOI":"10.1212\/WNL.57.8.1416","article-title":"Randomized trial of vigabatrin in patients with infantile spasms","volume":"57","author":"Elterman","year":"2001","journal-title":"Neurology"},{"key":"10.1016\/j.eplepsyres.2018.09.016_bib0035","doi-asserted-by":"crossref","first-page":"1340","DOI":"10.1177\/0883073810365103","article-title":"Vigabatrin for the treatment of infantile spasms: final report of a randomized trial","volume":"25","author":"Elterman","year":"2010","journal-title":"J. Child Neurol."},{"key":"10.1016\/j.eplepsyres.2018.09.016_bib0040","doi-asserted-by":"crossref","first-page":"522","DOI":"10.1111\/epi.13670","article-title":"Operational classification of seizure types by the International League Against Epilepsy: Position Paper of the ILAE Commission for Classification and Terminology","volume":"58","author":"Fisher","year":"2017","journal-title":"Epilepsia"},{"key":"10.1016\/j.eplepsyres.2018.09.016_bib0045","doi-asserted-by":"crossref","first-page":"32","DOI":"10.1016\/j.braindev.2015.05.012","article-title":"Predictive factors for relapse of epileptic spasms after adrenocorticotropic hormone therapy in West syndrome","volume":"38","author":"Hayashi","year":"2016","journal-title":"Brain Dev."},{"key":"10.1016\/j.eplepsyres.2018.09.016_bib0050","doi-asserted-by":"crossref","first-page":"108","DOI":"10.1001\/jamaneurol.2013.1858","article-title":"Reversible vigabatrin-induced life-threatening encephalopathy","volume":"71","author":"Hern\u00e1ndez Vega","year":"2014","journal-title":"JAMA Neurol."},{"key":"10.1016\/j.eplepsyres.2018.09.016_bib0055","doi-asserted-by":"crossref","first-page":"317","DOI":"10.1111\/j.1528-1157.1984.tb04195.x","article-title":"Hypsarrhythmia: variations on the theme","volume":"25","author":"Hrachovy","year":"1984","journal-title":"Epilepsia"},{"key":"10.1016\/j.eplepsyres.2018.09.016_bib0060","doi-asserted-by":"crossref","first-page":"103","DOI":"10.1111\/epi.12460","article-title":"Treatment of infantile spasms with very high dose prednisolone before high dose adrenocorticotropic hormone","volume":"55","author":"Hussain","year":"2014","journal-title":"Epilepsia"},{"key":"10.1016\/j.eplepsyres.2018.09.016_bib0065","doi-asserted-by":"crossref","first-page":"215","DOI":"10.1016\/j.jpeds.2017.08.009","article-title":"Recognition of infantile spasms is often delayed: the ASSIST study","volume":"190","author":"Hussain","year":"2017","journal-title":"J. Pediatr."},{"key":"10.1016\/j.eplepsyres.2018.09.016_bib0070","doi-asserted-by":"crossref","first-page":"674","DOI":"10.1111\/epi.13712","article-title":"Risk of vigabatrin-associated brain abnormalities on MRI in the treatment of infantile spasms is dose-dependent","volume":"58","author":"Hussain","year":"2017","journal-title":"Epilepsia"},{"key":"10.1016\/j.eplepsyres.2018.09.016_bib0075","doi-asserted-by":"crossref","first-page":"475","DOI":"10.1002\/ana.24594","article-title":"Response to treatment in a prospective national infantile spasms cohort","volume":"79","author":"Knupp","year":"2016","journal-title":"Ann. Neurol."},{"key":"10.1016\/j.eplepsyres.2018.09.016_bib0080","doi-asserted-by":"crossref","first-page":"1773","DOI":"10.1016\/S0140-6736(04)17400-X","article-title":"The United Kingdom Infantile Spasms Study comparing vigabatrin with prednisolone or tetracosactide at 14 days: a multicentre, randomised controlled trial","volume":"364","author":"Lux","year":"2004","journal-title":"Lancet"},{"key":"10.1016\/j.eplepsyres.2018.09.016_bib0085","doi-asserted-by":"crossref","first-page":"1359","DOI":"10.1111\/j.1528-1167.2011.03127.x","article-title":"The effect of lead time to treatment and of age of onset on developmental outcome at 4 years in infantile spasms: evidence from the United Kingdom Infantile Spasms Study","volume":"52","author":"O\u2019Callaghan","year":"2011","journal-title":"Epilepsia"},{"key":"10.1016\/j.eplepsyres.2018.09.016_bib0090","doi-asserted-by":"crossref","first-page":"33","DOI":"10.1016\/S1474-4422(16)30294-0","article-title":"Safety and effectiveness of hormonal treatment versus hormonal treatment with vigabatrin for infantile spasms (ICISS): a randomised, multicentre, open-label trial","volume":"16","author":"O\u2019Callaghan","year":"2017","journal-title":"Lancet Neurol."},{"key":"10.1016\/j.eplepsyres.2018.09.016_bib0095","doi-asserted-by":"crossref","first-page":"184","DOI":"10.1111\/j.1528-1167.2008.01728.x","article-title":"Cerebral MRI abnormalities associated with vigabatrin therapy","volume":"50","author":"Pearl","year":"2009","journal-title":"Epilepsia"},{"key":"10.1016\/j.eplepsyres.2018.09.016_bib0100","doi-asserted-by":"crossref","first-page":"2175","DOI":"10.1111\/j.1528-1167.2010.02657.x","article-title":"Infantile spasms: a U.S. Consensus report","volume":"51","author":"Pellock","year":"2010","journal-title":"Epilepsia"},{"key":"10.1016\/j.eplepsyres.2018.09.016_bib0105","doi-asserted-by":"crossref","first-page":"1280","DOI":"10.1111\/epi.13442","article-title":"Prevention of infantile spasms relapse: zonisamide and topiramate provide no benefit","volume":"57","author":"Rajaraman","year":"2016","journal-title":"Epilepsia"},{"key":"10.1016\/j.eplepsyres.2018.09.016_bib0110","doi-asserted-by":"crossref","first-page":"13","DOI":"10.1016\/j.ejpn.2009.03.004","article-title":"Favourable prognostic factors with infantile spasms","volume":"14","author":"Riikonen","year":"2010","journal-title":"Eur. J. Paediatr. Neurol."},{"key":"10.1016\/j.eplepsyres.2018.09.016_bib0115","doi-asserted-by":"crossref","first-page":"60","DOI":"10.1111\/dmcn.12573","article-title":"Does vigabatrin treatment for infantile spasms cause visual field defects? An international multicentre study","volume":"57","author":"Riikonen","year":"2015","journal-title":"Dev. Med. Child Neurol."},{"key":"10.1016\/j.eplepsyres.2018.09.016_bib0120","unstructured":"Sabril (vigabatrin) package insert, 2009."},{"issue":"Part A","key":"10.1016\/j.eplepsyres.2018.09.016_bib0125","doi-asserted-by":"crossref","first-page":"29","DOI":"10.1016\/j.yebeh.2016.01.012","article-title":"A lack of clinically apparent vision loss among patients treated with vigabatrin with infantile spasms: The UCLA experience","volume":"57","author":"Schwarz","year":"2016","journal-title":"Epilepsy Behav."},{"key":"10.1016\/j.eplepsyres.2018.09.016_bib0130","doi-asserted-by":"crossref","first-page":"63","DOI":"10.1111\/j.1535-7511.2006.00100.x","article-title":"Infantile spasms: little seizures, BIG consequences","volume":"6","author":"Shields","year":"2006","journal-title":"Epilepsy Curr."},{"key":"10.1016\/j.eplepsyres.2018.09.016_bib0135","doi-asserted-by":"crossref","first-page":"748","DOI":"10.1046\/j.1528-1157.2002.17801.x","article-title":"Visual field constriction in 91 Finnish children treated with vigabatrin","volume":"43","author":"Vanhatalo","year":"2002","journal-title":"Epilepsia"},{"key":"10.1016\/j.eplepsyres.2018.09.016_bib0140","doi-asserted-by":"crossref","first-page":"2262","DOI":"10.1212\/WNL.0000000000001069","article-title":"Vigabatrin retinal toxicity in children with infantile spasms: An observational cohort study","volume":"83","author":"Westall","year":"2014","journal-title":"Neurology"},{"key":"10.1016\/j.eplepsyres.2018.09.016_bib0145","doi-asserted-by":"crossref","first-page":"195","DOI":"10.1111\/j.1528-1167.2008.01896.x","article-title":"Magnetic resonance imaging abnormalities associated with vigabatrin in patients with epilepsy","volume":"50","author":"Wheless","year":"2009","journal-title":"Epilepsia"}],"container-title":["Epilepsy Research"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0920121118303516?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0920121118303516?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,12]],"date-time":"2025-10-12T13:39:52Z","timestamp":1760276392000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0920121118303516"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,12]]},"references-count":29,"alternative-id":["S0920121118303516"],"URL":"https:\/\/doi.org\/10.1016\/j.eplepsyres.2018.09.016","relation":{},"ISSN":["0920-1211"],"issn-type":[{"value":"0920-1211","type":"print"}],"subject":[],"published":{"date-parts":[[2018,12]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"High vigabatrin dosage is associated with lower risk of infantile spasms relapse among children with tuberous sclerosis complex","name":"articletitle","label":"Article Title"},{"value":"Epilepsy Research","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.eplepsyres.2018.09.016","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2018 Elsevier B.V. All rights reserved.","name":"copyright","label":"Copyright"}]}}